Your browser doesn't support javascript.
loading
Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760).
Leighl, Natasha B; Redman, Mary W; Rizvi, Naiyer; Hirsch, Fred R; Mack, Philip C; Schwartz, Lawrence H; Wade, James L; Irvin, William J; Reddy, Sreekanth C; Crawford, Jeffrey; Bradley, Jeffrey D; Stinchcombe, Thomas E; Ramalingam, Suresh S; Miao, Jieling; Minichiello, Katherine; Herbst, Roy S; Papadimitrakopoulou, Vassiliki A; Kelly, Karen; Gandara, David R.
Afiliação
  • Leighl NB; Division of Medical Oncology/Hematology, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada natasha.leighl@uhn.ca.
  • Redman MW; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Rizvi N; Thoracic Oncology, Columbia University Irving Medical Center, New York, New York, USA.
  • Hirsch FR; Center for Thoracic Oncology, Tisch Cancer Institute and Icahn School of Medicine Mount Sinai, New York, New York, USA.
  • Mack PC; Center for Thoracic Oncology, Tisch Cancer Institute and Icahn School of Medicine Mount Sinai, New York, New York, USA.
  • Schwartz LH; Department of Radiology, NewYork-Presbyterian/Columbia University Medical Center, New York, New York, USA.
  • Wade JL; Medical Oncology, Heartland NCORP, Decatur, Illinois, USA.
  • Irvin WJ; Hematology Oncology, Bon Secours Cancer Institute, Richmond, Virginia, USA.
  • Reddy SC; Medical Oncology/Hematology, Atlanta Cancer Care Centers, Atlanta, Georgia, USA.
  • Crawford J; Medical Oncology, Duke University Medical Center, Durham, North Carolina, USA.
  • Bradley JD; Department of Radiation Oncology, Washington University in St Louis School of Medicine, St Louis, Missouri, USA.
  • Stinchcombe TE; Medical Oncology, Duke University Medical Center, Durham, North Carolina, USA.
  • Ramalingam SS; Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.
  • Miao J; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Minichiello K; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Herbst RS; Medical Oncology, Yale Cancer Center | Yale School of Medicine | Smilow Cancer Hospital at Yale New Haven, New Haven, Connecticut, USA.
  • Papadimitrakopoulou VA; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Kelly K; Divison of Hematology and Oncology, Department of Medicine, University of California Davis Comprehensive Cancer Center, Sacramento, California, USA.
  • Gandara DR; Division of Hematology/Oncology, Department of Medicine, UC Davis Comprehensive Cancer Center, Sacramento, California, USA.
J Immunother Cancer ; 9(8)2021 08.
Article em En | MEDLINE | ID: mdl-34429332
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma de Células Escamosas / Protocolos de Quimioterapia Combinada Antineoplásica / Imunoterapia / Neoplasias Pulmonares Tipo de estudo: Clinical_trials / Guideline Limite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma de Células Escamosas / Protocolos de Quimioterapia Combinada Antineoplásica / Imunoterapia / Neoplasias Pulmonares Tipo de estudo: Clinical_trials / Guideline Limite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article